Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 1/20 | 0.48 |
| ▸ | CHRM1 known ✓ | P11229 | 1/20 | 0.40 |
| ▸ | GABRP known ✓ | O00591 | 2/20 | 0.38 |
| ▸ | GABRD known ✓ | O14764 | 2/20 | 0.38 |
| ▸ | GABRA1 known ✓ | P14867 | 2/20 | 0.38 |
| ▸ | GABRB1 known ✓ | P18505 | 2/20 | 0.38 |
| ▸ | GABRG2 known ✓ | P18507 | 2/20 | 0.38 |
| ▸ | GABRB3 known ✓ | P28472 | 2/20 | 0.38 |
| ▸ | GABRA5 known ✓ | P31644 | 2/20 | 0.38 |
| ▸ | GABRA3 known ✓ | P34903 | 2/20 | 0.38 |
| ▸ | GABRA2 known ✓ | P47869 | 2/20 | 0.38 |
| ▸ | GABRB2 known ✓ | P47870 | 2/20 | 0.38 |
| ▸ | GABRA4 known ✓ | P48169 | 2/20 | 0.38 |
| ▸ | GABRE known ✓ | P78334 | 2/20 | 0.38 |
| ▸ | GABRA6 known ✓ | Q16445 | 2/20 | 0.38 |
| ▸ | GABRG1 known ✓ | Q8N1C3 | 2/20 | 0.38 |
| ▸ | GABRG3 known ✓ | Q99928 | 2/20 | 0.38 |
| ▸ | GABRQ known ✓ | Q9UN88 | 2/20 | 0.38 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.35 |
| ▸ | MGAM | O43451 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL14920723 | 1.00 | MGAM (0.48) | MGAMGAASIMGAM2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL14920670 | 1.00 | MGAM (0.48) | MGAMGAASIMGAM2ALDH1A1 | |
| SCHEMBL7405660 | 0.98 | — | — | |
| SCHEMBL4846715 | 0.98 | — | — | |
| SCHEMBL2821 | 0.98 | — | — | |
| Hydrochloric Acid SCHEMBL3637939 | 0.84 | GAA (0.50) | MGAMGAASIMGAM2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL27969637 | 0.84 | SOAT1 (0.52) | MGAMGAASIMGAM2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL27530692 | 0.84 | SOAT1 (0.52) | MGAMGAASIMGAM2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL27988835 | 0.84 | SOAT1 (0.52) | MGAMGAASIMGAM2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL333918 | 0.83 | GAA (0.44) | MGAMGAASIMGAM2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12577226-B2 | Compounds for treating Huntington's disease | PTC THERAPEUTICS, INC. (US) | 2026-03-17 | — | — | US | disclosed |
| EP-3969446-B1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS INC (US) | 2023-09-27 | — | — | EP | disclosed |
| EP-4219466-A1 | COMPUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC Therapeutics, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11572341-B2 | Biguanide compound and use thereof | IMMUNOMET THERAPEUTICS INC. (US) | 2023-02-07 | — | — | US | disclosed |
| US-20220204478-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. | 2022-06-30 | — | — | US | disclosed |
| EP-3969446-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC Therapeutics, Inc. (US) | 2022-03-23 | — | — | EP | disclosed |
| WO-2020231977-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | PTC THERAPEUTICS, INC. (US) | 2020-11-19 | — | — | WO | disclosed |
| US-20200277255-A1 | BIGUANIDE COMPOUND AND USE THEREOF | IMMUNOMET THERAPEUTICS INC. | 2020-09-03 | — | — | US | disclosed |
| EP-3222614-B1 | BIGUANIDE COMPOUND AND USE THEREOF | IMMUNOMET THERAPEUTICS INC (US) | 2020-07-29 | — | — | EP | disclosed |
| US-10626085-B2 | Biguanide compound and use thereof | IMMUNOMET THERAPEUTICS INC. (US) | 2020-04-21 | — | — | US | disclosed |
| EP-0796245-A1 | PROCESS FOR THE PREPARATION OF AMIDINO PHENYL PYRROLIDINE $g(b)-ALANINE UREA ANALOGS | G.D. SEARLE & CO. (US) | 1997-09-24 | — | — | EP | disclosed |
| US-5659063-A | AMINE-BLOCKED METHIONINE ANALOG CYCLIZABLE TO A LACTAM IN NONVOLATILE OR NONTOXIC REAGENTS; ANTITHROMBOTIC AGENTS | G. D. SEARLE & CO. (US) | 1997-08-19 | — | — | US | disclosed |
| WO-1997024122-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-10 | — | — | WO | disclosed |
| WO-1997024124-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-10 | — | — | WO | disclosed |
| US-5610296-A | CHEMICAL INTERMEDIATES OF ANTITHROMBOTICS | G. D. SEARLE & CO. (US) | 1997-03-11 | — | — | US | disclosed |
| US-5576447-A | Process for the preparation of amidino phenyl pyrrolidine β-alanine urea analogs | G. D. SEARLE & CO. (US) | 1996-11-19 | — | — | US | disclosed |
| WO-1996017827-A1 | PROCESS FOR THE PREPARATION OF AMIDINO PHENYL PYRROLIDINE β-ALANINE UREA ANALOGS | G.D. SEARLE & CO. (US) | 1996-06-13 | — | — | WO | disclosed |
| EP-0691953-A1 | 1-AMIDINOPHENYL-PYRROLIDONES PIPERIDINONES AZETINONES AS PLATELET AGGREGATION INHIBITORS | G.D. SEARLE & CO. (US) | 1996-01-17 | — | — | EP | disclosed |
| US-5484946-A | CYCLIZATION AND DEHYDRATION A METHIONINE DERIVATIVE | G. D. SEARLE & CO. (US) | 1996-01-16 | — | — | US | disclosed |
| WO-1994022820-A1 | 1-AMIDINOPHENYL-PYRROLIDONES PIPERIDINONES AZETINONES AS PLATELET AGGREGATION INHIBITORS | G.D. SEARLE & CO. (US) | 1994-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204478-A1 | COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | HTT, HYPK, FH | GAA 11/4885CHRM1 3880/4885GABRP 2603/4885 |
| US-10626085-B2 | Biguanide compound and use thereof | MKI67, GCG, GCKR | GAA 788/4885CHRM1 3833/4885GABRP 3424/4885 |
| US-11572341-B2 | Biguanide compound and use thereof | MKI67, GCG, GCKR | GAA 788/4885CHRM1 3833/4885GABRP 3424/4885 |
| US-12577226-B2 | Compounds for treating Huntington's disease | HTT, HYPK, GRIN2C | GAA 334/4885CHRM1 546/4885GABRP 1340/4885 |
| US-20200277255-A1 | BIGUANIDE COMPOUND AND USE THEREOF | MKI67, GCG, GCKR | GAA 788/4885CHRM1 3833/4885GABRP 3424/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.